Crossmark

Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001–2018)

Crossref DOI link: https://doi.org/10.1186/s12936-019-2911-y

Published Online: 2019-08-22

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raman, Jaishree http://orcid.org/0000-0003-0728-3093
Kagoro, Frank M.

Mabuza, Aaron

Malatje, Gillian

Reid, Anthony

Frean, John

Barnes, Karen I.
Funding

Funding for this research was provided by:

National Institute for Communicable Diseases

South African Medical Research Council (Research Incentive)
License Information

Text and Data Mining valid from 2019-08-22

Version of Record valid from 2019-08-22
More Information

Article History

Received: 10 April 2019

Accepted: 13 August 2019

First Online: 22 August 2019

Ethics approval and consent to participate

: Approval for this study was obtained from the Mpumalanga Provincial Department of Health (MP_2015RP53_229), and the University of Witwatersrand Human Research Ethics Committee: Medical (M160229). It also met the criteria for studies of routinely-collected data of the Ethics Review Board of Médecins Sans Frontières.

: Permission for publication was received from the Manager of the Mpumalanga Provincial Malaria Elimination Programme.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below